QS Research · Michael Burry's Scion Capital analyst template · 2006
INSMED Inc (INSM)
As of 2026-11-20 · 12/15 boxes filled from SEC filings and market data
Report price $141.33 (close 2026-11-20)
Conclusion: PASS
Conviction low · base case none · downside -59% · upside +24%
At $141.33 the market is paying 20.02x TTM sales for a commercial-stage biopharma whose revenue is compounding but which has no positive operating income or operating cash flow, so the call rests on revenue and the price already discounts a long growth runway. That is why the call is PASS. The downside case is -58.6% to $58.45, from -30.0% sales at a compressed EV/Sales of 11.51x (today 20.02x). The upside case is +24.5% to $176.00, from +25% sales at today's EV/Sales of 20.02x. There is no base case: no comparable peer multiple or own-history multiple sets one, and a base at today's multiple is today's price by construction. The reverse DCF needs +19.1% revenue growth a year for 10 years against +66.7% in the latest fiscal year, so the growth is real but not yet an earnings-backed value case at this price.
Key numbers
- Share price: $141.33
- Market cap: $31.01B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $1.52B
- FCF yield: -2.0%
- Price / book: 42.69x
- Revenue growth (latest fiscal year): +66.7%
- ROIC (TTM): -262.7%
- WACC: 6.6%
- Economic profit spread: -269.3 pts
The 15 boxes
- ✓ 1. Long-form business notes
INSM is a commercial-stage biopharma whose FY2025 10-K shows two respiratory products, ARIKAYCE and BRINSUPRI, plus clinical programs in Respiratory, Immunology & Inflammation, and Neuro & Other Rare; the FY2020 10-K shows only ARIKAYCE commercial with brensocatib and TPIP clinical-stage. Revenue grew from $164.4M in FY2020 to $606.4M in FY2025 and $1.52B TTM to Sep 2026, but operating income stayed negative every year in the six-year data and was -$564.0M TTM; operating cash flow was also negative every year and -$595.6M TTM. For cyclical normalization, the sources show no positive operating earnings or operating cash flow to normalize, and no gross profit or product-level revenue is provided.
- ✓ 2. Competitive advantage
The advantage here is regulatory and clinical, not cost or scale: Insmed is the only approved therapy for NCFB in the US and EU with BRINSUPRI (US August 2025, EU November 2025) and, by its own account, has no approved inhaled competitor for refractory NTM lung infections, with ARIKAYCE strongly recommended in international guidelines. That moat has not converted into operating leverage: revenue went from $164.4M in FY2020 to $606.4M in FY2025 and $1.52B TTM to Sep 2026, while operating income was negative in every period and worsened to -$1.25B in FY2025 (-$564.0M TTM) and operating cash flow was negative every year FY2020-FY2025 (-$595.6M TTM). Normalized over the cycle there is no positive earnings or cash-flow base to defend, so the advantage rests on approvals, guideline position and time-limited exclusivity rather than on brand, cost or scale.
- ✓ 3. 10-Q takeaways
Q3 2026 revenue jumped to $524.4 million from $142.3 million a year earlier as BRINSUPRI US sales went from $28.1 million to $398.1 million, while ARIKAYCE grew 9% to $124.4 million; BRINSUPRI was up 29% sequentially. Cost of product revenues fell to 14.9% of revenue from 20.6%, but R&D rose 45% and SG&A 36%, so the quarter was still an operating loss of $89.4 million and a net loss of $100.3 million. Cash plus marketable securities totaled about $1.1 billion at September 30, 2026 against $1.43 billion at December 31, 2025, with $348.0 million of operating cash burned in the nine months. Full-year 2026 revenue guidance was raised for both products.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.